Individual Study / AtheroGene

AtheroGene

AtheroGene

Initiatives -
The objectives of the AtheroGene study: * To assess the value of clinical and molecular biomarkers for secondary prevention in patients with coronary artery disease. * To assess risk prediction across a wide range of coronary artery disease phenotypes with particular emphasis on the role of genetics. * The major endpoint in this study was cardiovascular death and non-fatal myocardial infarction among other cardiovascular outcomes.
Start Year
1996
End Year
2004
Funding
Stiftung Rheinland-Pfalz für Innovation, Ministry for Science and Education, Mainz, Germany (AZ 15202-386261/545); INSERM, Paris (to Dr. Blankenberg), and the Schleicher Stiftung, Dresdner Bank, Frankfurt, Germany.
Visit AtheroGene

Members

Download
Investigators Contacts
  • Dr. Prof. Stefan Blankenberg
    University Heart Center Hamburg
  • Dr. Prof. Tanja Zeller
    University Medical Center Hamburg-Eppendorf

Design

Study design
Population cohort
Follow Up
Median follow-up period of 4.2 years

Marker Paper

Zengin E, Bickel C, Schnabel RB, Zeller T,Lackner K-J, Rupprecht H-J, et al. (2015) Risk Factors of Coronary Artery Disease in Secondary Prevention—Results from the AtheroGene—Study. PLoS ONE 10(7): e0131434. doi:10.1371/journal.pone.0131434

Recruitment

Sources of Recruitment
  • Individuals

Number of participants

Number of participants
3,229
Number of participants with biosamples
Supplementary Information
Patients with suspected coronary artery disease

Access

Availability of data and biosamples

Data
Biosamples
Other